
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
For much of the AIDS epidemic, clinicians have prescribed injections of interleukin-2 (a compound that boosts immune system cellular production) to HIVers with persistently low CD4-cell levels. But studies on the treatment have been unclear about whether it truly is beneficial. Until now. Data from two large-scale international clinical trials presented at the 16th Conference on Retroviruses and Opportunistic Infections have shown that while IL-2 taken in addition to standard antiretroviral therapy does raise CD4-cell levels more than anti-HIV drugs alone, the increases do not convey any clinical benefit, such as reduced risks for HIV-related infections. Worse yet, the hard-to-tolerate IL-2 injections doubled chances for severe side effects during the first year of treatment. 'A potential clinical benefit of IL-2, even moderate, can be definitely ruled out,' concludes researcher Yves Levy, MD, Ph.D., who headed one of the clinical trials.
From our Sponsors
Most Popular
Plus: Featured Video